Roche aban­dons an­ti-myo­statin ap­proach to Duchenne MD — one more nail in the class' cof­fin

Roche has joined a line of drug­mak­ers re­treat­ing from one class of ex­per­i­men­tal Duchenne mus­cu­lar dy­s­tro­phy drugs, deal­ing an­oth­er blow to the the­o­ry that in­hibit­ing myo­statin can slow the mus­cle-wast­ing dis­ease.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER